Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Contrave achieves greater weight loss than placebo with no sign of plateau

Sep. 29, 2006

QR-333 administered safely in subjects with diabetic peripheral neuropathy

Sep. 29, 2006

Kalypsys advancing KD-3010 for metabolic disorders

Sep. 29, 2006

Preclinical insulinotropic efficacy and stability of novel GLP-1 and GIP analogues reported

Sep. 29, 2006

Hunter's syndrome patients benefit from idursulfase infusions

Sep. 29, 2006

Novel compounds with potential in the treatment of metabolic disorders patented

Sep. 28, 2006

Pharmacokinetics, efficacy and safety of sitagliptin in patients with type 2 diabetes

Sep. 28, 2006

Recent patents describe new agents for diabetes and related disorders

Sep. 28, 2006

Additional preclincal, clinical and pharmacokinetic data on denosumab presented

Sep. 28, 2006

MK-0364: Merck & Co.'s novel CB1 inverse agonist for the treatment of obesity

Sep. 27, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...